Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    Biologic DMARD Use May Lower Risk of Deadly Sepsis in RA Patients with Infections
    August 31, 2016August 31, 2016

    Biologic DMARD Use May Lower Risk of Deadly Sepsis in RA Patients with Infections

    News
    Biological disease-modifying anti-rheumatic drugs appear to more effectively reduce the risk of sepsis after serious infection in patients with rheumatoid arthritis (RA) than conventional drugs of this nature, researchers reported, based on a study ... Read more
    Predictors Identified for Severe Cervical Spine Instabilities in RA Patients
    August 29, 2016August 29, 2016

    Predictors Identified for Severe Cervical Spine Instabilities in RA Patients

    News
    Patients with rheumatoid arthritis (RA) are more likely to exhibit cervical spine instabilities if they have a history of corticosteroid treatment or joint surgery and the presence of mutilating changes, ... Read more
    Phase 3 Clinical Tests of Filgotinib in Range of RA Patients Getting Underway
    August 26, 2016August 26, 2016

    Phase 3 Clinical Tests of Filgotinib in Range of RA Patients Getting Underway

    News
    Galapagos NV has recently initiated a global Phase 3 clinical program (FINCH) evaluating the safety and efficacy of filgotinib (100 mg and 200 mg once daily) in a range of ... Read more
    Rheumatoid Arthritis Patients on Kineret at High Risk of Strep Infections, Study Says
    August 24, 2016August 24, 2016

    Rheumatoid Arthritis Patients on Kineret at High Risk of Strep Infections, Study Says

    News
    Rheumatoid arthritis patients using medications that are interleukin-1β (IL-1β) receptor antagonists, like Kineret (anakinra), may be at much higher risk of infections with Group A Streptococcal bacteria, a  flesh-eating bacteria that is the cause ... Read more
    Rheumatoid Arthritis Patients Could Develop Second Autoimmune Condition
    August 22, 2016August 30, 2016

    Rheumatoid Arthritis Patients Could Develop Second Autoimmune Condition

    News
    People with rheumatoid arthritis (RA) or other autoimmune diseases have a high likelihood of being impacted with a second autoimmune disorder. The question is why? Several explanations for the phenomenon were offered in ... Read more
    Johnson & Johnson to Appeal Court Ruling That Favors Biosimilar Competition
    August 19, 2016August 19, 2016

    Johnson & Johnson to Appeal Court Ruling That Favors Biosimilar Competition

    News
    In a press release, Johnson & Johnson announced recently that a District of Massachusetts Federal Court has ruled on a summary judgment motion filed by Celltrion Healthcare and Hospira Healthcare Corporation in patent ... Read more
    Heart Attack Risk for RA Patients Linked to C-Reactive Protein
    August 17, 2016August 17, 2016

    Heart Attack Risk for RA Patients Linked to C-Reactive Protein

    News
    Rheumatoid arthritis (RA) patients who present high levels of inflammation markers have an increased risk for myocardial infarction (heart attack) according to the study “Impact of disease activity and treatment of comorbidities ... Read more
    Chances for Heart Disease with Rheumatoid Arthritis May Decrease Via HDL Control
    August 15, 2016August 15, 2016

    Chances for Heart Disease with Rheumatoid Arthritis May Decrease Via HDL Control

    News
    Rheumatoid arthritis (RA) treatments can reduce the risk for cardiovascular diseases (CVD) when restoration of normal HDL anti-oxidant functions is achieved, according to researchers at the University of California Los Angeles ... Read more
    August 12, 2016August 12, 2016

    Lower-Cost Biosimilar Therapy Gets Unanimous FDA Panel Support

    News
     The US Food and Drug Administration’s (FDA) Arthritis Advisory Committee last month unanimously supported Amgen’s drug candidate ABP 501 as a biosimilar to Abbvie’s Humira (adalimumab). Amgen is seeking to ... Read more
    Cell Therapy Seen in Trial to Benefit RA Patients Who Don’t Respond to Biologics
    August 10, 2016August 10, 2016

    Cell Therapy Seen in Trial to Benefit RA Patients Who Don’t Respond to Biologics

    News
    Mesoblast has announced positive results of a Phase 2 clinical trial evaluating its lead mesenchymal precursor cell (MPC) therapy candidate, MPC-300-IV, in people with biologic refractory rheumatoid arthritis (RA). “The safety and ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.